Johns Hopkins University, The Clinical Trials Unit
Baltimore, Maryland, 21205, United States
NCT Number: NCT00244803
The purpose of this study is to learn whether HIV-infected patients have blood abnormalities which could lead to heart attack or stroke, and to find out what factors may contribute to these abnormalities.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Observational
Baltimore, Maryland, 21205, United States
This research is being done to learn whether HIV-infected patients have abnormalities in their blood vessels that could eventually lead to heart attack or stroke (atherosclerosis), in how fat is distributed in their body and in how their body handles fat and sugars. If there are abnormalities, this study will also try to find out what factors may contribute to those abnormalitites.
People who participated in FRAM 1 may join FRAM 2.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Johns Hopkins University
Other
Redistribution and Metabolic Change in HIV Infection: Protocol 2 (FRAM Fat 2)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06651957
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
San Francisco, California, United States
View Trial DetailsNCT03839212
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Miami, Florida, United States
View Trial DetailsNCT03823209
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Cleveland, Ohio, United States
View Trial DetailsNCT06176859
ART, Acquired Immunodeficiency Syndrome
Durban, KwaZulu-Natal, South Africa
View Trial Details